Vote Scores

Home / Companies / Kymera Therapeutics, Inc. / 24 Jun 2026

Meeting · year to 30 June 2026436 filers reporting

Kymera Therapeutics, Inc.: meeting of 24 Jun 2026

Votes reported on Form N-PX, item by item

436 Form N-PX filers reported votes at the Kymera Therapeutics, Inc. meeting of 24 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

4 nominees; 70.4% of reported votes for; 72 filers withheld from or voted against at least one nominee.

1,420 vote records from 181 filers. 43 of the 179 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

75.1% for0.0% against24.9% other24.0% against management181 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

692 vote records from 435 filers. 34 of the 410 filers that marked the item either way voted against management. 25 filers reported this item without a management mark.

86.0% for7.8% against6.2% other8.3% against management435 filers96.5% for3.4% against0.0% other3.5% against management109,909,698 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

355 vote records from 181 filers. 1 of the 179 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.3% for0.0% against1.7% other0.6% against management181 filers99.9% for0.0% against0.1% other0.1% against management34,333,919 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalAbstain or withhold *ForFor
State Street and SPDRForForFor
American CenturyAbstain or withhold *Against *For
Franklin TempletonForForFor
InvescoForAgainst *For
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsAbstain or withhold *ForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForFor
J.P. MorganForForFor
Goldman SachsForForFor
PGIM and PrudentialForForFor
Jackson National fundsForForFor
Northern Trust and FlexSharesForForFor
SEIForForFor
T. Rowe PriceForForFor
Lincoln FinancialForForFor
VoyaForForFor
First TrustAbstain or withhold *ForFor
Russell InvestmentsForForFor
NationwideForForFor
Victory CapitalAbstain or withhold *ForFor
Brighthouse FundsForForFor
Guggenheim and RydexAbstain or withhold *ForFor
Columbia ThreadneedleForForFor
BNY MellonAbstain or withhold *ForFor
PrincipalForForFor
Capital Group and American FundsForAgainst *For
Pacific Life fundsForForFor
Global XForForFor
MFSAbstain or withhold *ForFor
TransamericaForForFor
Federated HermesForForFor
AllianceBernsteinForForFor
Hartford FundsForForFor
DWSAbstain or withhold *ForFor
AllspringNo reportSplit or no voteNo report
MassMutualForForFor
Harbor FundsForForFor
VirtusAbstain or withhold *ForFor
Neuberger BermanForForFor
Natixis and Loomis SaylesNo reportForNo report
Lord AbbettNo reportForNo report
BairdNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Kymera Therapeutics, Inc. meeting?

436 Form N-PX filers reported votes at the meeting of 24 Jun 2026. On say-on-pay, 34 of 410 voted against management (8.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Kymera Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Kymera Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Kymera Therapeutics, Inc. with a meeting date within three days of 24 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.